Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07825376

Branching Scenario-Based Education in Coronary Artery Disease

This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Coronary Arterial Disease (CAD) Arterial Occlusive Diseases Arteriosclerosis Behavior Cardiovascular Diseases Coronary Artery Disease Coronary Disease Health Behavior Heart Diseases Myocardial Ischemia Treatment Adherence and Compliance Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bolu Abant İzzet Baysal University

Bolu, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-65 years.
  • Diagnosed with coronary artery disease.
  • Newly initiated on antiplatelet therapy.
  • Conscious and able to communicate.
  • Physically and cognitively able to use a virtual reality headset.
  • Able to read, write, and understand Turkish.
  • Willing to provide written informed consent.
  • Willing to participate in the education and follow-up process.
  • Has not previously received education about coronary artery disease.
  • Able to use a smartphone.

Exclusion criteria

  • Cognitive impairment or mental illness preventing communication.
  • Visual or hearing impairment preventing participation in the virtual reality education.
  • Participation in another clinical study at the same time.
  • Diagnosis of malignant disease.
  • Bleeding disorder or active bleeding risk.
  • Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event.
  • Unable to understand the educational materials.
  • Refusal to provide written informed consent.

Treatment and study plan

Virtual Reality-Based Branching Scenario Education

Behavioral

Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.

Tablet-Based Branching Scenario Education

Behavioral

Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.

Primary outcomes

  1. cardiovascular disease risk awareness assessment scale score

    Time frame: baseline and immediately after the educational intervention

    Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.

  2. medication adherence report scale score

    Time frame: Baseline, immediately after the intervention, and 3 months follow-up

    Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.

  3. Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire

    Time frame: Baseline, immediately after the intervention, and 3 months after the intervention.

    Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.

Study contacts

Contact information is provided by the study sponsor or research team.

Saadet Can Çiçek, PhD

CONTACT

[email protected]

+905062846936

Sponsors and collaborators

Lead sponsor

Abant Izzet Baysal University

Other

Registry information

Official study title

The Effect of Branching Scenario-Based Education Delivered Through Virtual Reality and Tablet on Cardiovascular Disease Risk Awareness and Antiplatelet Medication Adherence in Patients With Coronary Artery Disease: A Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 17, 2026
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.